What does mean by Tendinopathy?

Tendinopathy of the gluteus medius tendon is the main cause of greater trochanter pain syndrome, the incidence of which is reported to be1.8 patients per 1000 per year. As per the DelveInsight estimates, the United States has the highest diagnosed incident population of Tendinopathy.

Tendinopathy is still predominantly a medical condition that requires much patience from both therapist and patient. Nonoperative management should still be the first-line choice of treatment.

A variety of conservative treatments have been proposed to manage of tendinopathy, including physiotherapy and pharmacotherapy. This last class of intervention presents a growing number of injectable substances (corticosteroids, prolotherapy, autologous blood, platelet-rich plasma, polidocanol).

Check its Tendinopathy Market Share

Biophysical Treatments include Extracorporeal Shock Wave, Low-Intensity Pulsed Ultrasound, Laser Therapy; Injection Therapies are corticosteroids, Sclerotherapy, blood products; surgical treatment.

In the initial acute phase, rest and immobilization are considered to try and control exacerbating factors, but prolonged immobilization should be avoided. Moreover, training regimes modifications and specific exercises are necessary. NSAIDs inhibit tendon cell migration and proliferation and impair tendon healing. NSAIDs are nevertheless commonly used for the management of Achilles Tendinopathy, but have little or no effect on the clinical outcome.

Thermic treatments like Cryotherapy (e.g., ice packs and baths) and Thermotherapy (heat) are there. Few Achilles tendon injuries require surgical treatment, including suturing, implantation of autologous tissue (e.g., strip of the central aponeurosis of gastrocnemius, peroneal tendon, fascia lata, flexor digitorum longus or flexor halluces longus), an allograft or a synthetic scaffold.

Read @ Tendinopathy Market Size

Tendinopathy treatment is recommended to start with the less invasive ones, moving towards more invasive options if the conservative treatment fails. Targeted therapies for Tendinopathy have been lacking due to poor understanding of the underlying pathology. Accumulating data from several research centers are starting to unravel the pathophysiology of tendinosis and mechanisms that lead to tendon pain. Thus, novel targeted therapies are evolving. These new treatments, however, need to be clinically tested in adequate studies before generally applied.

The market size shall grow during the forecast period due to the increase in the Incident cases, with the better understanding of the disease and the emerging treatments.

The current emerging landscape for Tendinopathy is limited, mainly comprising of Phase II and Phase III candidate drugs. The key players for phase II and III clinical development are MiMedx Group, Ipsen, and others.

Original Source:- Tendinopathy Market Insights